FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2948859714> ?p ?o ?g. }

• W2948859714 endingPage "2214" @default.
• W2948859714 startingPage "2207" @default.
• W2948859714 abstract "The MORDOR I trial (Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance) showed that in Niger, mass administration of azithromycin twice a year for 2 years resulted in 18% lower postneonatal childhood mortality than administration of placebo. Whether this benefit could increase with each administration or wane owing to antibiotic resistance was unknown.In the Niger component of the MORDOR I trial, we randomly assigned 594 communities to four twice-yearly distributions of either azithromycin or placebo to children 1 to 59 months of age. In MORDOR II, all these communities received two additional open-label azithromycin distributions. All-cause mortality was assessed twice yearly by census workers who were unaware of participants' original assignments.In the MORDOR II trial, the mean (±SD) azithromycin coverage was 91.3±7.2% in the communities that received twice-yearly azithromycin for the first time (i.e., had received placebo for 2 years in MORDOR I) and 92.0±6.6% in communities that received azithromycin for the third year (i.e., had received azithromycin for 2 years in MORDOR I). In MORDOR II, mortality was 24.0 per 1000 person-years (95% confidence interval [CI], 22.1 to 26.3) in communities that had originally received placebo in the first year and 23.3 per 1000 person-years (95% CI, 21.4 to 25.5) in those that had originally received azithromycin in the first year, with no significant difference between groups (P = 0.55). In communities that had originally received placebo, mortality decreased by 13.3% (95% CI, 5.8 to 20.2) when the communities received azithromycin (P = 0.007). In communities that had originally received azithromycin and continued receiving it for an additional year, the difference in mortality between the third year and the first 2 years was not significant (-3.6%; 95% CI, -12.3 to 4.5; P = 0.50).We found no evidence that the effect of mass administration of azithromycin on childhood mortality in Niger waned in the third year of treatment. Childhood mortality decreased when communities that had originally received placebo received azithromycin. (Funded by the Bill and Melinda Gates Foundation; ClinicalTrials.gov number, NCT02047981.)." @default.
• W2948859714 created "2019-06-14" @default.
• W2948859714 creator A5004723861 @default.
• W2948859714 creator A5006338001 @default.
• W2948859714 creator A5009715006 @default.
• W2948859714 creator A5015714457 @default.
• W2948859714 creator A5024510654 @default.
• W2948859714 creator A5033288392 @default.
• W2948859714 creator A5038025520 @default.
• W2948859714 creator A5049197682 @default.
• W2948859714 creator A5052072975 @default.
• W2948859714 creator A5058005277 @default.
• W2948859714 creator A5069369290 @default.
• W2948859714 creator A5070363052 @default.
• W2948859714 creator A5071963296 @default.
• W2948859714 creator A5075952432 @default.
• W2948859714 creator A5080095497 @default.
• W2948859714 creator A5081280153 @default.
• W2948859714 creator A5087875655 @default.
• W2948859714 date "2019-06-06" @default.
• W2948859714 modified "2023-09-23" @default.
• W2948859714 title "Longer-Term Assessment of Azithromycin for Reducing Childhood Mortality in Africa" @default.
• W2948859714 cites W1978653163 @default.
• W2948859714 cites W1982375973 @default.
• W2948859714 cites W1982556454 @default.
• W2948859714 cites W2072217715 @default.
• W2948859714 cites W2108291388 @default.
• W2948859714 cites W2119425860 @default.
• W2948859714 cites W2126932416 @default.
• W2948859714 cites W2130937568 @default.
• W2948859714 cites W2134412546 @default.
• W2948859714 cites W2151869728 @default.
• W2948859714 cites W2158294771 @default.
• W2948859714 cites W2283259737 @default.
• W2948859714 cites W2513856537 @default.
• W2948859714 cites W2514545215 @default.
• W2948859714 cites W2549697535 @default.
• W2948859714 cites W2598433957 @default.
• W2948859714 cites W2726340707 @default.
• W2948859714 cites W2801239041 @default.
• W2948859714 cites W2884775202 @default.
• W2948859714 cites W2890046827 @default.
• W2948859714 cites W2895079403 @default.
• W2948859714 cites W2901408395 @default.
• W2948859714 cites W2905587610 @default.
• W2948859714 cites W3024150279 @default.
• W2948859714 cites W2099507563 @default.
• W2948859714 doi "https://doi.org/10.1056/nejmoa1817213" @default.
• W2948859714 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6512890" @default.
• W2948859714 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31167050" @default.
• W2948859714 hasPublicationYear "2019" @default.
• W2948859714 type Work @default.
• W2948859714 sameAs 2948859714 @default.
• W2948859714 citedByCount "53" @default.
• W2948859714 countsByYear W29488597142019 @default.
• W2948859714 countsByYear W29488597142020 @default.
• W2948859714 countsByYear W29488597142021 @default.
• W2948859714 countsByYear W29488597142022 @default.
• W2948859714 countsByYear W29488597142023 @default.
• W2948859714 crossrefType "journal-article" @default.
• W2948859714 hasAuthorship W2948859714A5004723861 @default.
• W2948859714 hasAuthorship W2948859714A5006338001 @default.
• W2948859714 hasAuthorship W2948859714A5009715006 @default.
• W2948859714 hasAuthorship W2948859714A5015714457 @default.
• W2948859714 hasAuthorship W2948859714A5024510654 @default.
• W2948859714 hasAuthorship W2948859714A5033288392 @default.
• W2948859714 hasAuthorship W2948859714A5038025520 @default.
• W2948859714 hasAuthorship W2948859714A5049197682 @default.
• W2948859714 hasAuthorship W2948859714A5052072975 @default.
• W2948859714 hasAuthorship W2948859714A5058005277 @default.
• W2948859714 hasAuthorship W2948859714A5069369290 @default.
• W2948859714 hasAuthorship W2948859714A5070363052 @default.
• W2948859714 hasAuthorship W2948859714A5071963296 @default.
• W2948859714 hasAuthorship W2948859714A5075952432 @default.
• W2948859714 hasAuthorship W2948859714A5080095497 @default.
• W2948859714 hasAuthorship W2948859714A5081280153 @default.
• W2948859714 hasAuthorship W2948859714A5087875655 @default.
• W2948859714 hasBestOaLocation W29488597141 @default.
• W2948859714 hasConcept C126322002 @default.
• W2948859714 hasConcept C142724271 @default.
• W2948859714 hasConcept C144024400 @default.
• W2948859714 hasConcept C149923435 @default.
• W2948859714 hasConcept C168563851 @default.
• W2948859714 hasConcept C187212893 @default.
• W2948859714 hasConcept C204787440 @default.
• W2948859714 hasConcept C27081682 @default.
• W2948859714 hasConcept C2778907293 @default.
• W2948859714 hasConcept C3017583242 @default.
• W2948859714 hasConcept C44249647 @default.
• W2948859714 hasConcept C501593827 @default.
• W2948859714 hasConcept C71924100 @default.
• W2948859714 hasConcept C86803240 @default.
• W2948859714 hasConcept C89423630 @default.
• W2948859714 hasConceptScore W2948859714C126322002 @default.
• W2948859714 hasConceptScore W2948859714C142724271 @default.
• W2948859714 hasConceptScore W2948859714C144024400 @default.
• W2948859714 hasConceptScore W2948859714C149923435 @default.
• W2948859714 hasConceptScore W2948859714C168563851 @default.

• next